Protalix BioTherapeutics (PLX) Retained Earnings (2010 - 2025)

Protalix BioTherapeutics' Retained Earnings history runs 16 years deep, the most recent figure standing at -$385.0 million for Q4 2025.

• In Q4 2025, Retained Earnings fell 1.75% year-over-year to -$385.0 million; the TTM figure through Dec 2025 stood at -$385.0 million (down 1.75% YoY), while the FY2025 annual figure was -$385.0 million, down 1.75% from the prior year.
• Retained Earnings was -$385.0 million for Q4 2025 at Protalix BioTherapeutics, down from -$378.4 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$374.9 million in Q4 2021 to a low of -$389.9 million in Q4 2022.
• Historically, Retained Earnings has averaged -$381.9 million across 5 years, with a median of -$381.5 million in 2023.
• The sharpest annual moves came in 2021 and 2023: Retained Earnings dropped 7.94% in 2021, then increased 2.13% in 2023.
• A 5-year view of Retained Earnings shows it stood at -$374.9 million in 2021, then decreased by 3.98% to -$389.9 million in 2022, then advanced by 2.13% to -$381.5 million in 2023, then advanced by 0.83% to -$378.4 million in 2024, then slipped by 1.75% to -$385.0 million in 2025.
• The last three Retained Earnings figures came in at -$385.0 million (Q4 2025), -$378.4 million (Q4 2024), and -$381.5 million (Q4 2023), per Business Quant data.